This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmidt, M. Articles by Gekeler, V. Search for Related Content PubMed PubMed Citation Articles by Schmidt, M. Articles by Gekeler, V.

Research Articles: Targets

Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells

¹ Therapeutic Area Oncology, ALTANA Pharma AG, Konstanz, Germany and ² Institut für Molekulare Medizin, Universität zu Lübeck, Lübeck, Germany

Requests for reprints: Mathias Schmidt, Therapeutic Area Oncology, ALTANA Pharma AG, Byk-Gulden-Str. 2, D-78467 Konstanz, Germany. Phone: 49-7531-842945; Fax: 49-7531-8492945. E-mail: mathias.schmidt{at}altanapharma.com

Abstract

Multiple roles within mitosis have been assigned to Polo-like kinase 1 (Plk1), making it an attractive candidate for mitotic targeting of cancer cells. We have employed chimeric antisense oligonucleotides to investigate the molecular alterations after targeted interference with Plk1 in RKO human colon adenocarcinoma and PC3 prostate cancer cells. Suppression of Plk1 mRNA resulted in a dramatic increase of the mitotic index followed by the onset of apoptosis. Mitotically arrested cells displayed randomly separated condensed chromosomes and the occurrence of multiple spindle poles with well-formed asters. Induction of apoptosis was strictly dependent on cell cycle progression: Genetically engineered RKO cells with inducible expression of the cyclin-dependent kinase inhibitor p27^Kip1 were completely refractory to Plk1 depletion-induced apoptosis when they were arrested in the G₁ phase of the cell cycle. Various mitotic markers, including MPM-2, cdc25c, cyclin B1, or phosphorylated histone H3, were investigated to explore the molecular consequences of Plk1 depletion. Whereas most marker proteins showed similar alterations compared with treatment with paclitaxel, cdc25c was fully phosphorylated solely in paclitaxel-treated cells but only partially phosphorylated in Plk1-depleted cells, although both treatments caused a profound mitotic arrest. This differential phosphorylation of cdc25c was used to test whether a pharmacologic inhibitor of Plk1 would exert the same cellular effects as interference with Plk1 on a mRNA level. It was found that the differential electrophoretic mobility of cdc25c can serve as a reliable molecular marker to track inhibition of Plk1 by small-molecule inhibitors within a cell. [Mol Cancer Ther 2006;5(4):809–17]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

³ Unpublished observations.

Received 11/ 3/05; revised 2/ 2/06; accepted 2/21/06.

This article has been cited by other articles:

				J. Fink, K. Sanders, A. Rippl, S. Finkernagel, T. L. Beckers, and M. Schmidt Cell type dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines Mol. Cancer Ther., December 1, 2007; 6(12): 3189 - 3197. [Abstract] [Full Text] [PDF]

				T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459. [Abstract] [Full Text] [PDF]